Clinical momentum Nektar is actively advancing lead asset rezpegaldesleukin in late-stage trials for atopic dermatitis and alopecia areata with substantial funding dedicated to Phase III development and manufacturing. This indicates ongoing near-term demand for strategic partnerships, CRO/CMO support, and scalable clinical trial services.

Funding runway A recent $250 million public offering funds expansion of R&D, clinical operations, and manufacturing capabilities. This suggests opportunities to engage with Nektar on contract manufacturing, supply chain optimization, and strategic collaborations to maximize capital efficiency.

Strategic partnerships Nektar emphasizes collaboration with leading pharmaceutical companies to translate research into therapies, signaling openness to co-development agreements, licensing deals, and data-sharing partnerships that could expand market access and accelerate commercialization.

Regulatory risk Multiple securities litigation matters and class-action filings in 2026 present potential diligence and governance considerations for partners. This underscores the need for robust compliance, risk assessment, and transparent program governance when engaging with Nektar.

Operational scale With approximately 501-1000 employees and an established tech stack (CRM, SAP, cloud and security tools), Nektar looks positioned to scale collaborations, data management, and manufacturing operations, suggesting opportunities for IT services, analytics platforms, and cloud-enabled collaboration solutions.